Novo Nordisk is pleased to announce that effective from 1 May 2025, Ryzodeg® Penfill® (insulin degludec/insulin aspart) is funded by PHARMAC without restriction for patients with either type 1 or type 2 diabetes.
Ryzodeg (insulin degludec/insulin aspart) is a combination of a long-acting and a rapid-acting insulin. It is accessible through the same channels as our other currently PHARMAC-funded insulin products.
Novo Nordisk would like to inform healthcare professionals and patients that NovoMix30® (biphasic insulin aspart) will be discontinued in mid-2026. PHARMAC has been notified regarding this planned discontinuation.
NovoMix30® (biphasic insulin aspart) was registered with MedSafe more than 22 years ago in February 2003. It is one of Novo Nordisk’s older generation products that we have decided to phase out in order to create capacity in our global manufacturing network for more innovative products in the future. Our goal remains to deliver medicines that will benefit and ultimately best serve the greatest number of patients globally.
We will continue to work with PHARMAC, MedSafe and clinicians to ensure alternative treatment options, either from Novo Nordisk or other companies, are available for patients so they can access the medication they need.
Novo Nordisk has advised Medsafe about the planned phase out of Novo Nordisk insulin products, which will occur over the next two years and will focus on older generation products with multiple presentations. This is part of a global insulin portfolio consolidation strategy and is not a result of any safety, efficacy or quality-related concerns.
The table below lists the products and presentations that will be impacted in New Zealand.
We remain committed to working closely with health authorities, the medical community, and patient advocacy groups, in accordance with local regulations, to ensure that patients have access to the medications they need.
We will provide support materials to healthcare professionals to assist patients transitioning to alternative treatments closer to the timings of each product phase-out.